Nov 12, 2021 This Week in Cardiology Podcast
This Week in Cardiology
Medscape Podcasts
4.9 • 963 Ratings
🗓️ 12 November 2021
⏱️ 23 minutes
🧾️ Download transcript
Summary
Left atrial appendage closure vs DOACs, TAVR vs SAVR, renal denervation, and an AHA 2021 preview are the topics John Mandrola, MD, discusses in this week's podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - LAAC
- PRAGUE-17: LAA Closure Holds Up Against DOACs Out to 4 Years https://www.medscape.com/viewarticle/962608
- LAAO vs DOAC: PRAGUE-17 Falls Short https://www.medscape.com/viewarticle/933641
- Left Atrial Appendage Closure versus Non-Warfarin Oral Anticoagulation in Atrial Fibrillation: 4-Year Outcomes of PRAGUE-17 https://www.jacc.org/doi/10.1016/j.jacc.2021.10.023
- Does Percutaneous Left Atrial Appendage Closure Stand the Test of Time? https://www.jacc.org/doi/10.1016/j.jacc.2021.10.022
II - SURTAVI (TAVR vs SAVR)
- SURTAVI at 5 Years Reinforces TAVR but Was It Long-term Enough? https://www.medscape.com/viewarticle/962484
- Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients https://www.nejm.org/doi/full/10.1056/NEJMoa1700456
III - Renal Denervation
- Renal Denervation Adds Clout to BP Meds in Resistant HTN: RADIANCE-HTN TRIO https://www.medscape.com/viewarticle/962508
- Renal Denervation Remains Only Promising in Meta-Analysis https://www.medscape.com/viewarticle/962369
- Renal Denervation for Hypertension: A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials https://doi.org/10.1016/j.jcin.2021.09.020
IV - AHA Preview
- AHA 2021 Puts Scientific Dialogue, Health Equity Center Stage https://www.medscape.com/viewarticle/962524
- Mandrola Previews the Virtual AHA 2021 https://www.medscape.com/viewarticle/962468
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Transcript
Click on a timestamp to play from that location
| 0:00.0 | You're listening to this week in cardiology from the heart.org on medscape. |
| 0:09.7 | You can now access the latest in medical news on your Amazon Alexa enabled device. |
| 0:14.3 | Join me, Perry Wilson, every weekday morning for Medscape Medical Minute, where I highlight |
| 0:18.8 | the top medical stories of the day. |
| 0:21.1 | To add Medscape Medical Minute to your flash briefing, search for Medscape |
| 0:24.4 | Medical Minute on Amazon and click enable. Or open the Amazon Alexa app, go to |
| 0:29.0 | skills, search for Medscape Medical Minute and click enable. Then say, |
| 0:33.4 | Alexa, what's the news or Alexa, what's my flash briefing? I hope you'll join us. |
| 0:38.6 | Hi everyone, this is John Mandrola from the Heart.org Medscape Cardiology and this is this week in |
| 0:45.1 | Cardiology for November 12th 2021. |
| 0:48.7 | This week, Left Atrial Appendage Closure, Taver versus Savar, |
| 0:54.0 | Reno, Denervation, and an AHA preview. |
| 0:58.3 | First topic is Left Atrial Appendage Closer |
| 1:01.1 | at the TCT meeting, Dr. Povel Osmancick from Prague presented the four-year results of Prague |
| 1:07.7 | 17, a non-inferiority trial of Left A Tril appendage closure versus direct acting oral |
| 1:14.6 | anticoagulants or doax in high-risk patients with AF. I recall that the |
| 1:19.8 | original Prague 17 was conducted in 10 centers in the Czech Republic. About |
| 1:24.7 | 415 patients were randomized and last year the investigators published |
| 1:29.8 | results of the 21-month follow-up. These were about 72-year-old patients. |
| 1:35.0 | Chad's Vask 4.7 has blood score of about 3.0. |
| 1:40.0 | And the original trial design was of non-inferiorityity and the non-inferiority margin was 1.47. |
| 1:47.0 | But the most controversial aspect of this trial was the broad composite end point that included both efficacy, stroke prevention, and safety |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.